Uveitis treatment market

Uveitis Treatment Market, by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), by Disease type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2020
CMI1094
186 Pages
Excel & Pdf
Medical Devices

Summary

Uveitis is an inflammation of the uvea, which is the middle layer of the eye that consists of iris, cilliary body and choroid. Based on the location where the inflammation occurs in the uvea, the condition can be classified as: anterior uveitis, intermediate uveitis, posterior uveitis, and diffuse uveitis. A middle layer of the eye inflammation (uvea). Iritis (anterior uveitis), an iris inflammation, is the most typical form. Redness, discomfort, light sensitivity, blurred vision, and dark floating patches in the field of vision are among the symptoms. Drops for the eyes are a typical remedy for irritation. Antibiotics or antiviral drugs may be provided if an infection caused the uveitis.

The global uveitis treatment market is estimated to be valued at US$ 710.0 Mn in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period (2022-2030).

Figure 1. Global Uveitis Treatment Market Share (%), by Disease Type, 2022

Global Uveitis Treatment Market– Drivers

High prevalence of uveitis is expected to propel growth of the global uveitis treatment over the forecast period. For instance, an article published in Frontiers in Medicine on September 10, 2021, the Pacific Ocular Inflammation Study found an annual incidence of uveitis of 24.9, while the Northern California study found an incidence of 52.4 cases of uveitis per 100,000 person-years.

The increase in high incidence of autoimmune disorders is expected to boost the growth of global uveitis treatment market over the forecast period. For instance, according to study done by John Hopkins University, department of pathology estimates suggest that all autoimmune diseases combined affect about 3% of the U.S. population every year, thus approximately 10 million people.

Uveitis Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 710.0 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.3%	2030 Value Projection:	US$ 1,075.0 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment Type: Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics By Disease Type: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Companies covered:	AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi, Regeneron Pharmaceuticals, and Inc., Alimera Sciences
Growth Drivers:	High prevalence of uveitis Increasing incidence of autoimmune disorders
Restraints & Challenges:	Challenging manufacturing process

Figure 2. Global Uveitis Treatment Market Share (%), by Region, 2022

Global Uveitis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

For instance, on June 23, 2021, an article published in National Library of Medicine suggest that, because of the connection to systemic disorders and the potential for irreversible vision loss, intermediate and posterior uveitis call for additional assessment and differential diagnosis accompanied by laboratory tests. When possible, ophthalmologists, especially those who specialize in uveitis, should provide treatment advice for iridocyclitis, intermediate, and posterior uveitis.

Global Uveitis Treatment Market: Key Developments

Increasing research initiatives for launch of phase 3 clinical trials by market players is expected to drive the global uveitis treatment market growth over the forecast period. For instance, on August 16, 2022 Tarsier Pharma, a pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular back and front of the eye blinding diseases, announces development Of TRS02, A Potential Immunomodulator, for the treatment of retinal diseases such as posterior uveitis (intermediate, posterior, and pan uveitis), diabetic macular edema, non-proliferative diabetic retinopathy, and dry-age-related macular degeneration.

Global Uveitis Treatment Market: Restraint

The challenging manufacturing process is expected to hinder the growth of global uveitis treatment over the forecast period. For instance, eye care product needs unique manufacturing process for making the product appropriately aligned with the GMP regulations for sterile products. Since the formulations are prone to get affected by the pathogens available in the environment, they are formulated under highly protected area.

Global Uveitis Treatment Market- Key Players

Major players operating in the global uveitis treatment market include AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi Regeneron Pharmaceuticals, Inc., and Alimera Sciences

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on “Global Uveitis Treatment Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global uveitis treatment market during the forecast period (2022-2030)?

Global uveitis treatment market size is estimated to be valued at US$ 710.0 million in 2022 and is expected to exhibit a CAGR of 5.3% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as high prevalence of uveitis and increase in high incidence of autoimmune disorders are expected to drive the market.

Which is the leading disease type segment in the market?

Anterior uveitis is the leading disease type segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include challenging manufacturing process.

Which are the major players operating in the market?

Major players operating in the market include AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi and Regeneron Pharmaceuticals, Inc., Alimera Sciences